InVivo Therapeutics Holdings Management
Management criteria checks 3/4
InVivo Therapeutics Holdings' CEO is Rich Toselli, appointed in Dec 2017, has a tenure of 6.42 years. total yearly compensation is $960.00K, comprised of 56% salary and 44% bonuses, including company stock and options. directly owns 0.008% of the company’s shares, worth $91.35. The average tenure of the management team and the board of directors is 12.9 years and 8.4 years respectively.
Key information
Rich Toselli
Chief executive officer
US$960.0k
Total compensation
| CEO salary percentage | 56.0% |
| CEO tenure | 6.4yrs |
| CEO ownership | 0.008% |
| Management average tenure | 12.9yrs |
| Board average tenure | 8.4yrs |
Recent management updates
Recent updates
InVivo Therapeutics dips 24% on $9M direct and private placement offerings
Oct 07We're Not Very Worried About InVivo Therapeutics Holdings' (NASDAQ:NVIV) Cash Burn Rate
Aug 26
Is InVivo Therapeutics Holdings (NASDAQ:NVIV) In A Good Position To Invest In Growth?
May 05Will InVivo Therapeutics Holdings (NASDAQ:NVIV) Spend Its Cash Wisely?
Jan 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$9m |
| Mar 31 2023 | n/a | n/a | -US$10m |
| Dec 31 2022 | US$960k | US$537k | -US$10m |
| Sep 30 2022 | n/a | n/a | -US$11m |
| Jun 30 2022 | n/a | n/a | -US$11m |
| Mar 31 2022 | n/a | n/a | -US$10m |
| Dec 31 2021 | US$1m | US$517k | -US$10m |
| Sep 30 2021 | n/a | n/a | -US$9m |
| Jun 30 2021 | n/a | n/a | -US$9m |
| Mar 31 2021 | n/a | n/a | -US$9m |
| Dec 31 2020 | US$870k | US$499k | -US$9m |
| Sep 30 2020 | n/a | n/a | -US$10m |
| Jun 30 2020 | n/a | n/a | -US$11m |
| Mar 31 2020 | n/a | n/a | -US$12m |
| Dec 31 2019 | US$1m | US$480k | -US$12m |
| Sep 30 2019 | n/a | n/a | -US$11m |
| Jun 30 2019 | n/a | n/a | -US$11m |
| Mar 31 2019 | n/a | n/a | -US$21m |
| Dec 31 2018 | US$929k | US$445k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$26m |
| Jun 30 2018 | n/a | n/a | -US$32m |
| Mar 31 2018 | n/a | n/a | -US$25m |
| Dec 31 2017 | US$1m | US$286k | -US$27m |
Compensation vs Market: Rich's total compensation ($USD960.00K) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Rich's compensation has been consistent with company performance over the past year.
CEO
Rich Toselli (65 yo)
6.4yrs
Tenure
US$960,003
Compensation
Dr. Richard M. Toselli, also known as Rich, M.D., serves as President, Chief Executive Officer and Director of InVivo Therapeutics Holdings Corp. since February 2, 2018 and has been its Chief Medical Offic...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.4yrs | US$960.00k | 0.0080% $ 91.3 | |
| CFO & Treasurer | 5.3yrs | US$583.78k | 0.0068% $ 77.7 | |
| Chief Legal Officer & General Counsel | no data | US$476.57k | 0.0011% $ 12.2 | |
| Co-Founder & Member of Scientific Advisory Board | 19.3yrs | no data | no data | |
| Co-Founder | 19.3yrs | no data | no data |
12.9yrs
Average Tenure
65yo
Average Age
Experienced Management: NVIV.Q's management team is seasoned and experienced (12.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.3yrs | US$960.00k | 0.0080% $ 91.3 | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.5yrs | US$68.01k | 0% $ 0 | |
| Independent Chair of the Board | 9.5yrs | US$87.38k | 0.0047% $ 54.3 | |
| Independent Director & Member of Scientific Advisory Board | 16.9yrs | US$58.01k | 0.00039% $ 4.5 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.9yrs | US$66.76k | 0% $ 0 | |
| Member of Scientific Advisory Board | 8.9yrs | no data | no data |
8.4yrs
Average Tenure
69yo
Average Age
Experienced Board: NVIV.Q's board of directors are considered experienced (8.4 years average tenure).